Home Page >
News and press releases >
News archive >
STAMPEDE launches abiraterone treatment arm
STAMPEDE launches abiraterone treatment arm
18 November 2011
The STAMPEDE
prostate cancer trial has launched protocol version 8.0, bringing
in a novel research arm to which patients could be allocated. The
new arm, G, involves Hormone Therapy in combination with
abiraterone, and was formally activated on Tuesday 15 November
2011.
Abiraterone is a CYP17 inhibitor manufactured
by Janssen. Previous results in castrate-refractory prostate cancer
have shown very promising results. STAMPEDE recruits in an earlier
setting: high-risk patients starting long-term hormone therapy for
the first time. Professor Johann de Bono, Chief Investigator of the
previous trials of abiraterone in castrate-refractory prostate
cancer, has described the addition of the abiraterone arm to
STAMPEDE as "a major day in prostate cancer history".
STAMPEDE, which implements novel multi-arm
multi-stage (MAMS) methods, is recruiting around 65 patients each
month; over 2600 patients had joined the trial by the end of
October 2011.
At present, the trial is recruiting to four
research arms and the control arm. Discussions are ongoing with
regards to further possible research arms.
A further change in protocol version 8.0
relates to the inclusion of radiotherapy for all patients with
newly diagnosed node-negative, non-metastatic disease. The change
follows the results of MRC PR07 (NCIC
PR.3), which were published in The
Lancet earlier this month.
More information can be found on the
STAMPEDE website and any
questions should be directed to the STAMPEDE team: stampede@ctu.mrc.ac.uk.
Further information
